The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

Z1051m  -  L-asparaginase

Escherichia coli O157:H7 str. EDL933

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Z1051m


High impact information on Z1051m


Chemical compound and disease context of Z1051m


Biological context of Z1051m


Anatomical context of Z1051m


Associations of Z1051m with chemical compounds

  • Asparaginase modified with N-acetylneuraminyl lactose, in contrast, with approximately 13.6 mol of N-acetylneuraminyl lactose/mol of enzyme, is cleared more slowly, with a t 1/2 that is approximately twice that of the native enzyme [17].
  • Two subclones were isolated, designated pDK1 and pDK2; the former complemented the partial defect in the utilization of aspartate, although its exact function was not established. pDK2 encoded the asparaginase I gene (ansA), the coding region of which was further defined within a 1.7-kilobase fragment [18].
  • Modification of cystine or tryptophan residues in the asparaginase molecule and their role in conformation and antigenicity [19].
  • Asparaginase activity was increased by the addition of L-glutamic acid, L-glutamine, or commercial-grade monosodium glutamate [20].
  • Spectroscopic characterization of the modified enzymes allowed the unequivocal assignment of the histidine resonances in 1H-NMR spectra of asparaginase II [21].

Analytical, diagnostic and therapeutic context of Z1051m


  1. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Swain, A.L., Jaskólski, M., Housset, D., Rao, J.K., Wlodawer, A. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  2. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Avramis, V.I., Sencer, S., Periclou, A.P., Sather, H., Bostrom, B.C., Cohen, L.J., Ettinger, A.G., Ettinger, L.J., Franklin, J., Gaynon, P.S., Hilden, J.M., Lange, B., Majlessipour, F., Mathew, P., Needle, M., Neglia, J., Reaman, G., Holcenberg, J.S., Stork, L. Blood (2002) [Pubmed]
  3. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Moghrabi, A., Levy, D.E., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Samson, Y., Schorin, M., Dalton, V.K., Lipshultz, S.E., Neuberg, D.S., Gelber, R.D., Cohen, H.J., Sallan, S.E., Silverman, L.B. Blood (2007) [Pubmed]
  4. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Duval, M., Suciu, S., Ferster, A., Rialland, X., Nelken, B., Lutz, P., Benoit, Y., Robert, A., Manel, A.M., Vilmer, E., Otten, J., Philippe, N. Blood (2002) [Pubmed]
  5. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. Woo, M.H., Hak, L.J., Storm, M.C., Sandlund, J.T., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Harrison, P.L., Wang, B., Evans, W.E., Pui, C.H., Relling, M.V. J. Clin. Oncol. (2000) [Pubmed]
  6. Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation. Jolivet, J., Cole, D.E., Holcenberg, J.S., Poplack, D.G. Cancer Res. (1985) [Pubmed]
  7. Role of Glutamine Depletion in Directing Tissue-specific Nutrient Stress Responses to L-Asparaginase. Reinert, R.B., Oberle, L.M., Wek, S.A., Bunpo, P., Wang, X.P., Mileva, I., Goodwin, L.O., Aldrich, C.J., Durden, D.L., McNurlan, M.A., Wek, R.C., Anthony, T.G. J. Biol. Chem. (2006) [Pubmed]
  8. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P., Buchanan, G.R. Blood (2000) [Pubmed]
  9. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Riccardi, R., Holcenberg, J.S., Glaubiger, D.L., Wood, J.H., Poplack, D.G. Cancer Res. (1981) [Pubmed]
  10. Crystal structure of isoaspartyl aminopeptidase in complex with L-aspartate. Michalska, K., Brzezinski, K., Jaskolski, M. J. Biol. Chem. (2005) [Pubmed]
  11. Enzyme-induced asparagine and glutamine depletion and immune system function. Kafkewitz, D., Bendich, A. Am. J. Clin. Nutr. (1983) [Pubmed]
  12. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Hawkins, D.S., Park, J.R., Thomson, B.G., Felgenhauer, J.L., Holcenberg, J.S., Panosyan, E.H., Avramis, V.I. Clin. Cancer Res. (2004) [Pubmed]
  13. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Avramis, V.I., Panosyan, E.H. Clinical pharmacokinetics. (2005) [Pubmed]
  14. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Woo, M.H., Hak, L.J., Storm, M.C., Gajjar, A.J., Sandlund, J.T., Harrison, P.L., Wang, B., Pui, C.H., Relling, M.V. J. Clin. Oncol. (1999) [Pubmed]
  15. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Werner, A., Röhm, K.H., Müller, H.J. Biol. Chem. (2005) [Pubmed]
  16. Asparaginase display of polypeptides in the periplasm of Escherichia coli: potential rapid pepscan technique for antigen epitope mapping. Gaofu, Q., Jie, L., Rongyue, C., Xin, Y., Dan, M., Jie, W., Xiangchun, S., Qunwei, X., Roque, R.S., Xiuyun, Z., Jingjing, L. J. Immunol. Methods (2005) [Pubmed]
  17. Glycosylation of Escherichia coli L-asparaginase. Marsh, J.W., Denis, J., Wriston, J.C. J. Biol. Chem. (1977) [Pubmed]
  18. L-asparaginase genes in Escherichia coli: isolation of mutants and characterization of the ansA gene and its protein product. Spring, K.J., Jerlström, P.G., Burns, D.M., Beacham, I.R. J. Bacteriol. (1986) [Pubmed]
  19. Modification of cystine or tryptophan residues in the asparaginase molecule and their role in conformation and antigenicity. Saito, T., Obata, M., Todokora, K., Okubo, M., Minowa, M. FEBS Lett. (1976) [Pubmed]
  20. Effect of culture conditions on synthesis of L-asparaginase by Escherichia coli A-1. Barnes, W.R., Dorn, G.L., Vela, G.R. Appl. Environ. Microbiol. (1977) [Pubmed]
  21. Site-specific mutagenesis of Escherichia coli asparaginase II. None of the three histidine residues is required for catalysis. Wehner, A., Harms, E., Jennings, M.P., Beacham, I.R., Derst, C., Bast, P., Röhm, K.H. Eur. J. Biochem. (1992) [Pubmed]
  22. Comparative pharmacokinetic studies of three asparaginase preparations. Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E., Cohen, H.J. J. Clin. Oncol. (1993) [Pubmed]
  23. Biosensor for asparagine using a thermostable recombinant asparaginase from Archaeoglobus fulgidus. Li, J., Wang, J., Bachas, L.G. Anal. Chem. (2002) [Pubmed]
  24. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Woo, M.H., Hak, L.J., Storm, M.C., Evans, W.E., Sandlund, J.T., Rivera, G.K., Wang, B., Pui, C.H., Relling, M.V. Leukemia (1998) [Pubmed]
  25. A catalytic role for threonine-12 of E. coli asparaginase II as established by site-directed mutagenesis. Harms, E., Wehner, A., Aung, H.P., Röhm, K.H. FEBS Lett. (1991) [Pubmed]
WikiGenes - Universities